In vitro testing is any experiment or test performed outside a living organism, typically in a controlled lab setting using cells, tissues, or biological samples in dishes, test tubes, or other lab equipment. The Latin phrase “in vitro” literally means “in glass,” a reference to the glass containers scientists originally used. It’s one of the most common approaches in medicine, drug development, and diagnostics, and you’ve almost certainly encountered it, whether through a routine blood test or hearing about IVF (in vitro fertilization).
How In Vitro Differs From In Vivo
The simplest way to understand in vitro testing is to compare it with in vivo testing, which means “in the living.” In vivo experiments happen inside a whole, living organism, such as an animal or a human in a clinical trial. In vitro experiments isolate a piece of that biology: a cluster of cells, a sample of blood, a protein sitting in a solution. By removing that piece from the body, scientists can study it under tightly controlled conditions without the thousands of variables that exist in a living system.
That isolation is both the strength and the weakness. In vitro tests let researchers zero in on a single reaction or mechanism with precision. But they sacrifice the complexity of a real body, where organs communicate with each other, the immune system responds in real time, and metabolism changes a drug’s structure as it circulates. A compound that kills cancer cells in a dish may behave differently once it enters a bloodstream.
Where You Encounter In Vitro Testing
In vitro testing touches more of everyday healthcare than most people realize. The broadest category is in vitro diagnostics (IVD), which the FDA defines as tests performed on samples like blood or tissue taken from the body. A basic blood panel checking your cholesterol, a PCR test detecting a virus, a biopsy analyzed for cancer cells: all of these are in vitro diagnostics. They’re used to detect diseases, monitor overall health, and increasingly to guide precision medicine by identifying which patients are likely to respond to specific treatments.
In vitro fertilization is another well-known application. During IVF, mature eggs are collected from the ovaries and fertilized with sperm in a lab rather than inside the body. The fertilized eggs develop into embryos over two to six days, then one or more embryos are transferred to the uterus. If successful, an embryo implants in the uterine lining about 6 to 10 days after egg retrieval. The “in vitro” label simply refers to that critical fertilization step happening in a lab dish instead of a fallopian tube.
The Role in Drug Development
In vitro testing is the workhorse of early drug discovery. Before a potential drug ever reaches a human volunteer, it goes through rounds of lab-based screening that can take years. The process typically starts with biological assays, lab tests designed to measure whether a molecule interacts with a specific disease target. These assays often use engineered cell lines that produce the protein a drug is meant to act on, or purified proteins set up in what are called biochemical assays.
Cell-based assays generate a functional readout, showing what actually happens in a cell when a compound is present. Biochemical assays, by contrast, often just measure how tightly a compound binds to its target protein. Promising molecules, called “hits,” move to secondary assays that test their effects in more disease-relevant cell systems. This layered screening narrows millions of candidate molecules down to a handful worth investigating further.
Once researchers identify lead compounds, in vitro tests shift toward safety and practicality. A suite of assays evaluates how well a compound dissolves in water, how quickly liver enzymes break it down, whether it can cross cell membranes (important for oral drugs that need to be absorbed from the gut), and whether it’s toxic to liver cells. These tests provide early warning signs that a drug might fail in humans, saving years of development time and significant costs.
High-Throughput Screening
One major advantage of in vitro testing is speed. High-throughput screening (HTS) technology uses miniaturized, automated platforms to test thousands or even millions of compounds against a biological target in a short period. These systems rely on robotics, computerized data processing, and sensitive detection equipment to run experiments at a scale that would be impossible in living organisms. HTS has become essential in drug discovery for identifying new drug candidates, and it’s also used in enzyme engineering and genetic research.
Key Limitations
For all its advantages, in vitro testing has significant blind spots. One of the hardest challenges is incorporating metabolism. In a living body, the liver transforms drugs into different chemical forms, some active, some toxic. Replicating that process in a dish is extremely difficult. Researchers who study liver cells extensively in lab settings have found it nearly impossible to reproduce certain metabolic switches that occur naturally in the organ.
Other well-documented limitations include the difficulty of capturing interactions between different cell types, the challenge of translating doses used in a dish to doses that matter in a body, and the near impossibility of simulating long-term exposure. Organs have complex architecture that allows them to compensate for stress in ways isolated cells cannot. A liver, for example, can reroute metabolic pathways when one is overwhelmed. That resilience is lost when you study liver cells in isolation. These gaps are why in vitro results alone have never been sufficient to approve a drug or declare a substance safe.
Organ-on-a-Chip Technology
A new generation of in vitro tools is closing some of those gaps. Organ-on-a-chip systems are small devices that culture living human cells in structures designed to mimic the physical environment of real organs, complete with fluid flow and mechanical forces. One platform, developed by a company called Emulate, can culture up to 96 independent organ-chip samples in a single run using a benchtop instrument launched in 2025. The company’s liver chip demonstrated 87% sensitivity and 100% specificity for detecting drug-induced liver injury in a published study, outperforming animal models on that measure.
These systems aim to deliver biological depth closer to what you’d see in a living body while keeping the speed and control of a lab environment. They cut consumable costs roughly fourfold and reduce hands-on lab work by about half compared to earlier organ-chip technology.
Regulatory Shifts Toward In Vitro Methods
The regulatory landscape is actively shifting in favor of in vitro approaches. The FDA announced a plan to phase out animal testing requirements for certain drug categories, including monoclonal antibodies. Under this plan, the agency encourages companies to submit data from what it calls New Approach Methodologies (NAMs), which include cell-based and organoid toxicity testing, AI-powered computer models that predict how drugs behave, and organ-on-a-chip systems that mimic human organs like the liver, heart, and immune system.
Companies that submit strong safety data from these non-animal methods may receive streamlined review, creating a financial incentive to invest in better in vitro platforms. The FDA is also beginning to accept real-world safety data from other countries with comparable regulatory standards when a drug has already been studied in humans elsewhere. Implementation for new drug applications has already begun, with inclusion of NAMs data encouraged immediately.
These changes don’t mean in vitro testing will fully replace animal or human studies anytime soon. But they mark a significant expansion in how regulators value lab-based evidence, particularly as organ-chip and computational tools mature to the point where they can predict human responses with increasing reliability.